博瑞医药：全资子公司BGM0504片获得药物临床试验批准通知书

Core Viewpoint - The company, Borui Pharmaceutical, announced that its wholly-owned subsidiary, Borui Pharmaceutical, has received the Clinical Trial Approval Notice from the National Medical Products Administration for BGM0504 tablets, which will be tested in adult overweight/obese patients [1] Group 1 - BGM0504 is a dual agonist of GLP-1 and GIP receptors, designed to activate downstream pathways of GIP and GLP-1, producing biological effects such as blood sugar control, weight loss, and treatment of non-alcoholic fatty liver disease (NASH) [1] - The injectable form of BGM0504 is currently in Phase III clinical trials for two indications: type 2 diabetes and weight loss [1] - As of the date of the announcement, there are no approved oral formulations targeting the same receptor in the global market [1]